![]() |
![]() |
||||||
![]() |
|||||||
![]() |
![]() |
|||||||||||||||||||||||||||||
|
![]()
CLICK ON weeks 0 - 40 and follow along every 2 weeks of fetal development
|
||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
Home | Pregnancy Timeline | News Alerts |News Archive Jul 8, 2015
|
Autism affects neural pathways and brain shape Scientists have found that mutations that cause autism in children are connected to a neural pathway regulating brain shape during fetal development. Researchers studying a set of well-known autism mutations called copy number variants or CNVs, found when and where these genes are expressed (turned on) in brain development is significant. "One surprising thing that we immediately observed was that different CNVs seemed to be turned on in different developmental periods," said Lilia Iakoucheva, PhD, assistant professor in the Department of Psychiatry, at the University of California, San Diego School of Medicine, and leader of the research. Her work is published in Neuron. Specifically, the team noted that one copy number variation (CNV) located in a genome region known as 16p11.2, contained genes that turn on (become active) during the later part of the mid-fetal period. Ultimately, they identified a network of genes showing a similar pattern of activation including KCTD13 within the same region 16p11.2 — and CUL3, a gene from a different chromosome but also mutated in children with autism.
Further experiments confirmed that CUL3 mutations disrupt interaction with the KCTD13 gene, which suggests that the 16p11.2 copy number variation (CNV) and CUL3 mutation could be acting via the same RhoA pathway. RhoA levels influence head and body size in zebrafish, a model animal used by geneticists to investigate gene function. Children with 16p11.2 copy number variations (CNVs) also have enlarged or decreased head sizes and suffer from obesity or are underweight. "Our model fits perfectly with what we observe in patients," adds Guan Ning Lin, PhD, a fellow in Iakoucheva's laboratory and co-first author along with Roser Corominas, PhD.
Iakoucheva and colleagues are planning to test inhibitors of the RhoA pathway using a stem cell model of autism. Abstract Co-authors include Xinping Yang, David E. Hill and Marc Vidal, Dana-Farber Cancer Institute; Irma Lemmens and Jan Tavernier, Ghent University, Belgium; and Jonathan Sebat, Beyster Center for Genomics of Psychiatric Diseases and UCSD. This research was funded, in part, by National Institutes of Health (grants R01MH091350, R01HD065288, R21MH104766 and R01MH105524).
|